TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04270812

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Sleep and Circadian Intervention for Youth (TranS-C)
Description: TranS-C adopts a modular approach to reversing the psychosocial, behavioral, and cognitive processes maintaining sleep problems via 4 cross-cutting modules (introduced in the first session and included in every session thereafter), 4 core modules and 7 optional modules. TranS-C typically involves 6-8 individual, weekly 50-minute sessions.
Study: NCT01958905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine fixed combination
Study: NCT01499485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Daily morning ABGA:~* If actual bicarbonate \> 26 mmol/L and pH \> 7.35: administration of enteral capsule of acetazolamide 500 mg .~* If actual bicarbonate \> 26 mmol/L and pH \<= 7.35, increase minute ventilation to reach pH \> 7.35 and then administer enteral capsule of acetazolamide 500 mg.~* If actual bicarbonate \<= 26 mmol/L: omit treatment that day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily morning ABGA:~* If actual bicarbonate \> 26 mmol/L and pH \> 7.35: administration of enteral capsule of placebo.~* If actual bicarbonate \> 26 mmol/L and pH \<= 7.35, increase minute ventilation to reach pH \> 7.35 and then administer enteral capsule of placebo.~* If actual bicarbonate \<= 26 mmol/L: omit treatment that day.
Study: NCT05116436

Intervention type: PROCEDURE
Intervention: Blood sample
Description: It will test the presence or absence of genetic mutations found in other cohorts in previous studies.
Study: NCT04508582

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Imaging of the heart with ultrasound.
Study: NCT05116436

Intervention type: PROCEDURE
Intervention: Blood sample
Description: It will test the presence or absence of genetic mutations found in other cohorts in previous studies.

Intervention type: PROCEDURE
Intervention: Spine X-ray
Description: To determine the scoliosis

Intervention type: PROCEDURE
Intervention: Spine X-ray
Description: To determine the scoliosis
Study: NCT00758446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLX-028914
Description: 50 mg capsules, p.o, daily, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLX-028914
Description: 15 mg capsules, p.o, daily, 14 days
Study: NCT04508582

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Imaging of the heart with ultrasound.

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Imaging of the heart with ultrasound.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Time- matched blood samples will be taken from patients to assess immune cell phenotype and function, paying particular attention to neutrophil and T-cell phenotype. Plasma samples will be collected for the analyses of cardiac specific factors (BNP, troponin) as well as measurement of steroid hormones (progesterone and oestradiol), and soluble inflammatory and anti-inflammatory mediators

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Time- matched blood samples will be taken from patients to assess immune cell phenotype and function, paying particular attention to neutrophil and T-cell phenotype. Plasma samples will be collected for the analyses of cardiac specific factors (BNP, troponin) as well as measurement of steroid hormones (progesterone and oestradiol), and soluble inflammatory and anti-inflammatory mediators

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Time- matched blood samples will be taken from patients to assess immune cell phenotype and function, paying particular attention to neutrophil and T-cell phenotype. Plasma samples will be collected for the analyses of cardiac specific factors (BNP, troponin) as well as measurement of steroid hormones (progesterone and oestradiol), and soluble inflammatory and anti-inflammatory mediators
Study: NCT01134952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate to sirolimus switch
Description: Sirolimus given for 3 months instead of mycophenolate at a starting dose equivalent of 1 mg sirolimus equal to 1000 mg of mycophenolate.
Study: NCT03668223

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting Resilience in Stress Management (PRISM)
Description: Manualized skills training targeting resilience resources: stress-management, goal-setting, cognitive reframing, and meaning-making
Study: NCT00758446

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: capsules, p.o, daily, 14 days
Study: NCT04502732

Intervention type: OTHER
Intervention: NSSM and GEBT
Description: The time to half gastric emptying (T1/2) will be assessed via Gastric Emptying Breath Tests (GEBT) and Nuclear Scintigraphy of a Solid Meal (NSSM) at baseline, 2 months, and 6 months. This data will be collected from seven adult subjects, with obesity, who have recently received Endoscopic Bariatric and Metabolic Therapy.
Study: NCT00685516

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: green tea
Description: 6 cups of green tea daily for 2-8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 6 cups of water daily for 2-8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: decaffeinated black tea
Description: 6 cups of decaffeinated black tea daily for 2-8 weeks
Study: NCT04122261

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the MicroHand S endoscopic instrument control system
Description: Using the MicroHand S endoscopic instrument control system to treat gallstone or cholecystitis in minimal invasive surgery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the da Vinci endoscopic instrument control system
Description: Using the da Vinci endoscopic instrument control system to treat gallstone or cholecystitis in minimal invasive surgery.
Study: NCT01792739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei variety rhamnosus granules
Description: Lactobacillus casei variety rhamnosus granules~: 3 gram per day (1g-1g-1g, 3 times per day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo granules~: 3 gram per day (1g-1g-1g, 3 times per day)
Study: NCT05410678

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Renal stent
Description: renal stent implantation in ectatic/aneurysmatic coronary arteries

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Renal stent
Description: renal stent implantation in ectatic/aneurysmatic coronary arteries
Study: NCT00109863

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hu14.18-IL2 fusion protein
Study: NCT03471052

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Description: Ablation using the Barrx RFA System is a new technique for field ablation in the oesophagus. It has been used for eradication of diseased epithelium of all three subclasses of Barrett's oesophagus (non-dysplastic Intestinal metaplasia (IM), Low grade dysplasia (LGD) and High grade dysplasia (HGD). The BarrxTM RFA System uses ultra short pulse RF energy delivering 40Watts/cm2 power density and 12Joule/cm2 energy density, and affects the mucosa whilst preserving the submucosa.~Clinical trials have suggested that it is safe and effective for treating non-dysplastic IM, LGD and HGD in Barrett's oesophagus . Long term data show the effect to be durable over 5 years.
Study: NCT03384589

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV13
Description: Vaccine against pneumococcal disease

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV13
Description: Vaccine against pneumococcal disease
Study: NCT02394626

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery followed by adjuvant second-line therapy
Description: Surgery:~Surgery must take place between day 1 and 14 after study inclusion and within 21 days from the MRI on which recurrence was diagnosed. The modalities of surgery and the choice of pre- and intra-operative technical adjuncts is at the treating neurosurgery discretion. Surgery must take place between day 1 and 14 after study inclusion and within 21 days from the MRI on which recurrence was diagnosed. The modalities of surgery and the choice of pre- and intra-operative technical adjuncts is at the treating neurosurgery discretion. However, some form of intra-operative resection control (iMRI or intra-operative fluorescence) and function control (electrophysiology) should be available to the surgeon and used when warranted.~Adjuvant second-line therapy:~Patients will be seen after surgery by the treating neurooncologist. Modalities of adjuvant second-line therapy are individually defined according to local guidelines and are not stipulated by study protocol.
Study: NCT00249834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human chorionic gonadotrophin (r-hCG)
Description: When at least 1 follicle greater than or equal to (\>=) 18 millimeter (mm) and 2 follicles \>=16 mm in diameter develop, 250 microgram (mcg) of recombinant human chorionic gonadotrophin (r-hCG) will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human chorionic gonadotrophin (r-hCG)
Description: When at least 1 follicle greater than or equal to (\>=) 18 millimeter (mm) and 2 follicles \>=16 mm in diameter develop, 250 microgram (mcg) of recombinant human chorionic gonadotrophin (r-hCG) will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human chorionic gonadotrophin (r-hCG)
Description: When at least 1 follicle greater than or equal to (\>=) 18 millimeter (mm) and 2 follicles \>=16 mm in diameter develop, 250 microgram (mcg) of recombinant human chorionic gonadotrophin (r-hCG) will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human chorionic gonadotrophin (r-hCG)
Description: When at least 1 follicle greater than or equal to (\>=) 18 millimeter (mm) and 2 follicles \>=16 mm in diameter develop, 250 microgram (mcg) of recombinant human chorionic gonadotrophin (r-hCG) will be administered.
Study: NCT00254436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procrit (epoetin alfa)
Description: Weekly dose
Study: NCT03541837

Intervention type: DRUG
Group type: OTHER
Intervention: Ropivacaine
Description: ESP catheter
Study: NCT00594776

Intervention type: DEVICE
Intervention: Cone Beam CT Scan
Description: The Cone Beam Computerized Tomographic (CBCT) device utilizes computerized tomographic technology, a special digital imaging plate and a computer to create a three-dimensional image. The special imaging plate and software allow for small details to be imaged without tissue overlap.
Study: NCT03391752

Intervention type: COMBINATION_PRODUCT
Intervention: Integrated Nutrition Pathway for Acute Care
Description: algorithm to guide care processes with respect to nutrition e.g. screening on admission, diagnosis with subjective global assessment, early treatment with medication pass of oral nutritional supplement

Intervention type: COMBINATION_PRODUCT
Intervention: Integrated Nutrition Pathway for Acute Care
Description: algorithm to guide care processes with respect to nutrition e.g. screening on admission, diagnosis with subjective global assessment, early treatment with medication pass of oral nutritional supplement

Intervention type: COMBINATION_PRODUCT
Intervention: Integrated Nutrition Pathway for Acute Care
Description: algorithm to guide care processes with respect to nutrition e.g. screening on admission, diagnosis with subjective global assessment, early treatment with medication pass of oral nutritional supplement

Intervention type: COMBINATION_PRODUCT
Intervention: Integrated Nutrition Pathway for Acute Care
Description: algorithm to guide care processes with respect to nutrition e.g. screening on admission, diagnosis with subjective global assessment, early treatment with medication pass of oral nutritional supplement

Intervention type: COMBINATION_PRODUCT
Intervention: Integrated Nutrition Pathway for Acute Care
Description: algorithm to guide care processes with respect to nutrition e.g. screening on admission, diagnosis with subjective global assessment, early treatment with medication pass of oral nutritional supplement

Intervention type: COMBINATION_PRODUCT
Intervention: Integrated Nutrition Pathway for Acute Care
Description: algorithm to guide care processes with respect to nutrition e.g. screening on admission, diagnosis with subjective global assessment, early treatment with medication pass of oral nutritional supplement

Intervention type: COMBINATION_PRODUCT
Intervention: Integrated Nutrition Pathway for Acute Care
Description: algorithm to guide care processes with respect to nutrition e.g. screening on admission, diagnosis with subjective global assessment, early treatment with medication pass of oral nutritional supplement

Intervention type: COMBINATION_PRODUCT
Intervention: Integrated Nutrition Pathway for Acute Care
Description: algorithm to guide care processes with respect to nutrition e.g. screening on admission, diagnosis with subjective global assessment, early treatment with medication pass of oral nutritional supplement

Intervention type: COMBINATION_PRODUCT
Intervention: Integrated Nutrition Pathway for Acute Care
Description: algorithm to guide care processes with respect to nutrition e.g. screening on admission, diagnosis with subjective global assessment, early treatment with medication pass of oral nutritional supplement
Study: NCT00496340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: Pre-conditioning therapy:~All participants will receive pentostatin 4 mg/m\^2 on day -28. Patients may receive additional doses on days -21 \& -14 depending on cell counts.~Participant will receive pentostatin at a dose of 4 mg/m\^2 by intravenous infusion over 1-2 hours on days -4, -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Pre-conditioning therapy:~Intravenous Busulfan (1st dose) at a dose of 200mg/m\^2 on day -4.~Intravenous Busulfan (2nd dose) will be administered on day (-2) to target a total AUC of 16,000 +/- 1600.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Pre-conditioning therapy:~Patients with CD20+ expressing malignancies will be treated with rituximab at a dose of 375 mg/m\^2 according to prescribing and institutional guidelines.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Cell Transplant
Description: Hematopoietic progenitor cells to be infused at least 36 hours after last dose of Busulfan.
Study: NCT02809365

Intervention type: DEVICE
Group type: OTHER
Intervention: FreeStyle Libre
Description: Addition of FreeStyle Libre system for 10 weeks to the treatment of uncontrolled Type 2 diabetic patients currently on multiple daily injections

Intervention type: DEVICE
Group type: OTHER
Intervention: personal glucometer
Description: Subjects in the Control Group will measure blood glucose levels by personal glucometer (SMBG = self monitoring blood glucose)
Study: NCT02528474

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: balloon angioplasty with Pantera Lux
Description: Patient will be considered to be enrolled if ISR in DES was found by angiography. After randomization, patients will be treated with Pantera Lux for treatment of ISR. OCT will be performed just after balloon angioplasty for ISR lesion. Information will be collected and recorded on the treated study vessel including angiographic and OCT parameters. Follow-up OCT at 9 month will be performed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balloon angioplasty with SeQuent Please
Description: Patient will be considered to be enrolled if ISR in DES was found by angiography. After randomization, patients will be treated with SeQuent Please for treatment of ISR. OCT will be performed just after balloon angioplasty for ISR lesion. Information will be collected and recorded on the treated study vessel including angiographic and OCT parameters. Follow-up OCT at 9 month will be performed.
Study: NCT02394626

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Second-line therapy alone
Description: Patients randomized to the non-surgical cohort receive second-line therapy according to local guidelines. Modalities thereof are not stipulated by study protocol.
Study: NCT04302974

Intervention type: PROCEDURE
Intervention: Different structures and processes of primary care management strategies
Description: Different structures and processes of primary care management strategies includes: Multi-morbidity, continuity-of-care, different service delivery models and management strategies (i.e. investigation frequency and specific drug regimens)

Intervention type: PROCEDURE
Intervention: Multi-disciplinary Risk Factor Assessment and Management Programmes for diabetes (RAMP-DM)
Description: Under the Multi-disciplinary Risk Factor Assessment and Management Programmes (RAMP) for diabetes (RAMP-DM), multi-disciplinary teams of health care professionals (doctors, nurses, dietitians, pharmacists, opticians etc) were established at designated GOPCs. All DM patients are eligible to enrol into the DM RAMP programmes. Each patient in the RAMP receives a comprehensive risk factor and complication screening to determine his/her overall cardiovascular risk and presence of modifiable risk factors, and according to their risk level and need, the patient may receive additional interventions such as additional counselling by the nurse or additional consultations with a senior doctor.

Intervention type: PROCEDURE
Intervention: Multi-disciplinary Risk Factor Assessment and Management Programmes for hypertension (RAMP-HT)
Description: Under the Multi-disciplinary Risk Factor Assessment and Management Programmes (RAMP) for hypertension (RAMP-HT), multi-disciplinary teams of health care professionals (doctors, nurses, dietitians, pharmacists, opticians etc) were established at designated GOPCs. All HT patients are eligible to enrol into the HT RAMP programmes. Each patient in the RAMP receives a comprehensive risk factor and complication screening to determine his/her overall cardiovascular risk and presence of modifiable risk factors, and according to their risk level and need, the patient may receive additional interventions such as additional counselling by the nurse or additional consultations with a senior doctor.

Intervention type: PROCEDURE
Intervention: Patient Support Call Centre (PSCC)
Description: RAMP Patients can also be referred to the Patient Empowerment Programme(PEP) - a structured self-care education programme delivered by non-governmental organisations(NGOs). If the DM control is suboptimal but the patient is unable to attend the PEP, they may be referred to the Patient Support Call Centre(PSCC) service. PSCC provides individualized telephone counselling by trained nurses. PSCC empowers high-risk DM patients to engage in self-care behaviours by providing regular protocol-led telephone support to advise and reinforce healthy behaviours. Targeted self-care behaviours include self-monitoring, medication management, balanced diet, exercise, risk factor reduction, problem solving and healthy coping. Enrolled patients receive weekly to bi-weekly calls in the first 3 months and additional calls as required for a maximum of 9 months. Subsequent follow-up calls are undertaken to assess self-care behaviours related to the selected goals and to develop a care plan with the patient.
Study: NCT02758782

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Golimumab

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Golimumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Study: NCT01307956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection
Study: NCT04821830

Intervention type: DRUG
Intervention: carbidopa/levodopa, as prescribed by treating physician
Description: There will be 4 measurement states:~at baseline prior to chronic treatment initiation (OFF-No LDR); at baseline after a standard, acute oral dose (25/250 carbidopa/L-dopa), referenced in the protocol, but prescribed and provided by their prescribing physician as standard of care initial dosage (ON-No LDR); 2 months after initiation of chronic, stable L-dopa treatment (amounts and sequences as prescribed by treating physicians) but with no L-dopa for 10-12 hours prior to evaluation (Practical OFF- LDR); and after resuming subjects' usual physician-prescribed L-dopa dose (ON-LDR).
Study: NCT02535936

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 3Tesla MRI with DTI-MRI and rsfcMRI under general anesthesia
Description: 2 post-operative MRI's at 2 months and 12 months
Study: NCT02666976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole
Description: Patients who were diagnosed clinically as NERD and were treated with ilaprazole 20mg once daily for 4 weeks. Biopsies were obtained from 3cm above the EG junction before and after treatment. GERD Q questionnaire, histologic findings (basal cell hyperplasia, papillary elongation, dilated intercellular spaces, intraepithelial eosinophils and intraepithelial T lymphocyte) and inflammatory biomarkers (TNF-α, IL-8, IL-1β, TRPV1 and MCP-1) were accessed.
Study: NCT03514550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol will be used for anesthesia during surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane will be used for anesthesia during surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural block
Description: Epidural catheterization Th9-Th10, ropivacaine for perioperative analgesia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural block
Description: Epidural catheterization Th9-Th10, ropivacaine for perioperative analgesia
Study: NCT01418339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole tablet administered orally once a week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Aripiprazole-matching placebo tablet administered orally once a week.